Details of the Drug

General Information of Drug (ID: DMPU2WX)

Drug Name
Omacetaxine mepesuccinate
Synonyms Synribo (TN)
Indication
Disease Entry ICD 11 Status REF
Adult acute monocytic leukemia N.A. Approved [1]
Chronic myelogenous leukaemia 2A20.0 Approved [1]
Chronic myeloid leukaemia 2A20 Approved [2]
Leukemia N.A. Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
L01XX40: Omacetaxine mepesuccinate
L01XX: Other antineoplastic agents
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 545.6
Logarithm of the Partition Coefficient (xlogp) 0.8
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.96 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 6 hours [3]
Metabolism
The drug is metabolized via the hepatic []
Vd
The volume of distribution (Vd) of drug is 141 +/- 93.4 L []
Chemical Identifiers
Formula
C29H39NO9
IUPAC Name
1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
Canonical SMILES
CC(C)(CCC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O
InChI
InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1
InChIKey
HYFHYPWGAURHIV-JFIAXGOJSA-N
Cross-matching ID
PubChem CID
285033
ChEBI ID
CHEBI:71019
CAS Number
26833-87-4
UNII
6FG8041S5B
DrugBank ID
DB04865
TTD ID
D0M4XY
ACDINA ID
D01298
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ribosome A (hRA) TTA4FIU NOUNIPROTAC Modulator [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) OTG0TTX7 CD38_HUMAN Gene/Protein Processing [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [6]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [7]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Gene/Protein Processing [6]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Protein Interaction/Cellular Processes [6]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Protein Interaction/Cellular Processes [6]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Protein Interaction/Cellular Processes [6]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Gene/Protein Processing [5]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Gene/Protein Processing [6]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Gene/Protein Processing [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 109 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 -6.5552 -5.1332 -6.5552 83.8375
JK1 CTRP2 -6.3794 -1.3072 -6.4006 78.4986
JM1 CTRP2 -5.8612 -2.6906 -5.8619 78.2613
EoL-1 CTRP2 -9.2826 -6.5964 -9.2826 95.3416
697 CTRP2 -8.9051 -6.5818 -8.9051 94.9121
Daudi CTRP2 -8.7078 -5.8085 -8.7079 93.0054
BL-70 CTRP2 -8.472 -6.2008 -8.472 93.3871
OCI-AML-3 CTRP2 -8.4022 -6.4846 -8.4022 93.7945
EB1 CTRP2 -8.334 -4.8617 -8.3343 90.39
RL CTRP2 -8.1172 4.1909 -8.9468 74.0643
GA-10 CTRP2 -8.0744 -6.0629 -8.0744 92.1073
MOLT-3 CTRP2 -7.7797 -6.4236 -7.7797 91.5365
SUP-B15 CTRP2 -7.7248 -4.4967 -7.7251 88.2344
MOLT-13 CTRP2 -7.3989 -2.7726 -7.406 84.1319
Hs 611.T CTRP2 -7.3707 -4.969 -7.3707 87.8516
Kasumi-1 CTRP2 -7.2993 -5.607 -7.2993 88.3396
OCI-Ly19 CTRP2 -7.0521 -3.7237 -7.0527 84.7401
ST486 CTRP2 -6.9092 -5.7317 -6.9092 86.2224
MOLT-16 CTRP2 -6.7812 -6.0272 -6.7812 85.4423
Kasumi-2 CTRP2 -6.7689 -4.2425 -6.7689 84.307
BCP-1 CTRP2 -6.6185 -4.3325 -6.6185 83.6717
OCI-AML-5 CTRP2 -6.5743 -5.8696 -6.5743 84.0666
OCI-Ly3 CTRP2 -6.512 -5.2404 -6.512 83.5973
KMS-20 CTRP2 -6.5118 -4.1329 -6.5119 82.94
MHH-CALL-4 CTRP2 -6.508 -2.117 -6.5155 80.2366
Pfeiffer CTRP2 -6.4401 -4.7788 -6.4401 82.9982
MOLM-6 CTRP2 -6.4361 -5.0231 -6.4361 83.0641
F-36P CTRP2 -6.4304 -4.1834 -6.4304 82.5606
MOLP-8 CTRP2 -6.4175 -3.5028 -6.4177 81.8158
M-07e CTRP2 -6.3955 -4.3478 -6.3955 82.4948
OCI-Ly10 CTRP2 -6.3778 -1.7996 -6.3885 79.2724
HL-60 CTRP2 -6.3713 -3.8067 -6.3714 81.9158
SIG-M5 CTRP2 -6.3348 -5.9599 -6.3348 82.4717
NU-DUL-1 CTRP2 -6.3296 -5.3293 -6.3296 82.4278
SEM CTRP2 -6.3149 -5.3516 -6.3149 82.3325
KMS-12-BM CTRP2 -6.274 -4.9048 -6.274 82.0121
BV-173 CTRP2 -6.267 -5.1685 -6.267 82.005
Karpas-422 CTRP2 -6.1802 -3.6265 -6.1803 80.7679
CA46 CTRP2 -6.1733 -3.2088 -6.1736 80.3287
SU-DHL-6 CTRP2 -6.1521 -4.9315 -6.1521 81.2315
OPM-2 CTRP2 -6.087 -4.7127 -6.087 80.7796
AML-193 CTRP2 -6.0612 -5.0877 -6.0612 80.6451
OCI-AML-2 CTRP2 -5.9846 -5.1105 -5.9846 80.1373
L-363 CTRP2 -5.9767 -4.7514 -5.9767 80.0691
MOTN-1 CTRP2 -5.9523 -2.8977 -5.9528 78.922
MOLM-16 CTRP2 -5.853 -4.5978 -5.853 79.2459
MJ CTRP2 -5.852 3.6441 -6.3707 69.6205
Granta-519 CTRP2 -5.7835 -1.4459 -5.7933 76.4397
SUP-M2 CTRP2 -5.7111 -4.961 -5.7111 78.3165
MC116 CTRP2 -5.6959 -4.8146 -5.6959 78.2145
A4/Fukuda CTRP2 -5.6759 -4.0459 -5.6759 78.0239
NB4 CTRP2 -5.6291 -5.0979 -5.6291 77.7705
NU-DHL-1 CTRP2 -5.5735 -2.2505 -5.5749 76.3883
RCH-ACV CTRP2 -5.5409 -0.0548 -5.5886 73.5819
A3/Kawakami CTRP2 -5.5278 -5.0813 -5.5278 77.0953
JeKo-1 CTRP2 -5.5118 -3.9646 -5.5118 76.9542
L-540 CTRP2 -5.4959 -4.6457 -5.4959 76.8829
Mono-Mac-1 CTRP2 -5.3959 -1.6085 -5.4004 74.8686
MOLP-2 CTRP2 -5.3856 -3.1834 -5.3856 75.9633
RPMI-6666 CTRP2 -5.3744 -4.0397 -5.3744 76.063
SET-2 CTRP2 -5.2665 -1.7252 -5.2694 74.3338
THP-1 CTRP2 -5.2163 -3.2736 -5.2163 74.9362
KMS-18 CTRP2 -5.0393 -2.4118 -5.0396 73.5488
RS4;11 CTRP2 -4.977 -2.3507 -4.9773 73.1491
MM1.S CTRP2 -4.9511 -3.1828 -4.9511 73.2174
DB CTRP2 -4.9484 -2.4305 -4.9485 73.01
L-428 CTRP2 -4.9163 -1.8161 -4.9175 72.5075
RPMI-8226 CTRP2 -4.7168 -3.0402 -4.7168 71.6732
EJM CTRP2 -4.5508 -1.641 -4.5517 70.2806
KMS-11 CTRP2 -4.4938 -2.6757 -4.4938 70.182
PL21 CTRP2 -4.4136 -1.662 -4.4142 69.4572
Reh CTRP2 -4.3858 -2.5777 -4.3858 69.4664
Namalwa CTRP2 -4.3689 -2.7006 -4.3689 69.363
LP-1 CTRP2 -4.277 -1.5076 -4.2777 68.5641
KO52 CTRP2 -4.1903 -0.6906 -4.1955 67.6858
Ci-1 CTRP2 -4.0469 -1.8646 -4.047 67.1833
KMS-28BM CTRP2 -3.9079 7.6617 -5.2979 59.872
K-562 CTRP2 -3.7649 1.7167 -3.8609 63.7259
HuT 78 CTRP2 -3.7281 1.0036 -3.7736 64.0502
SUP-T1 CTRP2 -3.6541 0.4432 -3.6745 63.9813
HPB-ALL CTRP2 -3.4707 -0.6813 -3.4721 63.2846
Ri-1 CTRP2 -3.4349 0.1132 -3.444 62.8385
Karpas-299 CTRP2 -3.4237 -1.9238 -3.4237 63.0762
SKM-1 CTRP2 -3.4146 -2.6985 -3.4146 63.0172
AMO1 CTRP2 -3.407 -2.7097 -3.407 62.9666
SU-DHL-4 CTRP2 -3.3917 -2.7455 -3.3917 62.8644
U-937 CTRP2 -3.3825 -2.1838 -3.3825 62.8035
SUP-HD1 CTRP2 -3.3498 1.3955 -3.4049 61.7398
NOMO-1 CTRP2 -3.3473 -1.0197 -3.3476 62.5348
SR CTRP2 -3.3412 -2.533 -3.3412 62.5283
KYO-1 CTRP2 -3.2592 0.3622 -3.2708 61.6818
HEL 92.1.7 CTRP2 -3.2439 -0.9059 -3.2443 61.8485
TF-1 CTRP2 -3.0405 -0.3831 -3.0418 60.4696
CMK CTRP2 -2.9417 2.0126 -3.024 59.1393
SUP-T11 CTRP2 -2.8619 4.4938 -3.3001 57.5037
HD-MY-Z CTRP2 -2.8566 0.2428 -2.8617 59.1937
TALL-1 [Human adult T-ALL] CTRP2 -2.413 8.9952 -4.1313 53.9178
GDM-1 CTRP2 -2.3671 9.3213 -4.2003 53.6645
OCI-M1 CTRP2 -2.3506 7.2299 -3.4665 54.1222
SK-MM-2 CTRP2 -2.217 5.1351 -2.7405 54.0658
Mino CTRP2 -2.031 3.8945 -2.2884 53.3541
ME1 CTRP2 -0.7736 3.3181 -0.8669 45.5857
Mono-Mac-6 CTRP2 -0.1805 23.121 -8.1092 47.105
MHH-CALL-3 CTRP2 0.3823 22.6839 -7.363 45.6672
P3HR-1 CTRP2 1.3308 15.0065 -2.787 40.0919
Karpas-620 CTRP2 7.9244 9.1723 5.6404 0.1357
REC-1 CTRP2 8.1093 10.5521 5.1902 1.0743
Toledo CTRP2 8.5842 29.5099 -3.6447 26.7529
BL-41 CTRP2 8.6409 31.5477 -4.6133 28.2567
⏷ Show the Full List of 109 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 -2.5416 1.2791 -2.5663 56.9993
TE8 CTRP2 -2.5212 0.058 -2.5228 57.0381
OE21 CTRP2 -6.3185 -3.5088 -6.3187 81.3518
EC-GI-10 CTRP2 -4.8344 0.4194 -4.8844 70.0385
TE-5 CTRP2 -4.4249 -0.3724 -4.4375 68.7844
OE33 CTRP2 -3.7282 1.3523 -3.7948 63.8084
KYSE-70 CTRP2 -3.2557 -1.7292 -3.2557 61.9573
TE-11 CTRP2 -2.9974 -0.2011 -2.9995 60.1671
TE-14 CTRP2 -2.767 -0.0376 -2.7691 58.6538
TE-6 CTRP2 -2.7593 1.2564 -2.7886 58.348
TE-4 CTRP2 -2.577 0.3159 -2.5807 57.3812
KYSE-510 CTRP2 -2.5069 -0.7044 -2.507 56.9681
KYSE-450 CTRP2 -2.4656 0.7465 -2.4743 56.6104
KYSE-520 CTRP2 -1.8498 4.2965 -2.1643 52.2598
KYSE-150 CTRP2 -1.7146 -0.3578 -1.7146 51.6917
KYSE-410 CTRP2 -1.3025 3.978 -1.5185 49.035
KYSE-30 CTRP2 -1.0645 1.8572 -1.0771 47.3792
TE-1 CTRP2 -0.1407 4.2087 -0.3075 41.6215
OE19 CTRP2 2.4071 12.0873 -0.3646 32.7528
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 -1.7265 2.3181 -1.7798 51.7117
MIA PaCa-2 CTRP2 -6.3786 -1.4307 -6.3967 78.6932
PaTu 8988s CTRP2 -6.2296 4.222 -6.9006 69.9406
Hs 766T CTRP2 -6.0921 3.9868 -6.7008 69.8645
Panc 08.13 CTRP2 -3.7974 0.9588 -3.8429 64.4526
HuP-T3 CTRP2 -3.5255 4.5052 -4.0231 60.5141
PSN1 CTRP2 -3.5126 2.2371 -3.6449 62.0718
Panc 03.27 CTRP2 -3.1065 -1.169 -3.1066 60.9571
PANC-1 CTRP2 -3.0216 2.8814 -3.1996 59.1431
HPAC CTRP2 -2.6528 0.332 -2.6573 57.8703
DAN-G CTRP2 -2.4742 0.8526 -2.4851 56.6507
Panc 10.05 CTRP2 -1.9699 5.8406 -2.647 52.658
PaTu 8988t CTRP2 -1.9308 3.4613 -2.1141 52.8493
PK-59 CTRP2 -1.7652 1.6786 -1.7866 51.9952
SU.86.86 CTRP2 -1.4553 1.5814 -1.4674 49.9641
Capan-1 CTRP2 -1.346 6.1735 -2.0565 49.3891
L3.3 CTRP2 -1.2547 1.4104 -1.2606 48.6334
Capan-2 CTRP2 -1.0982 6.9748 -2.0231 48.14
SW1990 CTRP2 -0.7474 6.7857 -1.5826 46.2101
Panc 04.03 CTRP2 -0.71 4.5363 -0.9766 45.4182
HuP-T4 CTRP2 -0.4076 3.0335 -0.4577 43.1084
Panc 02.03 CTRP2 -0.1838 9.6326 -1.9837 44.1871
PK-45H CTRP2 -0.1514 9.9266 -2.066 44.142
AsPC-1 CTRP2 0.6163 9.3628 -1.0281 39.9149
YAPC CTRP2 0.6914 7.1935 -0.1473 37.9135
Panc 05.04 CTRP2 0.9652 4.1701 0.8782 34.1217
KP-2 CTRP2 3.0544 14.9475 -1.0918 32.5979
TCC-Pan2 CTRP2 3.2478 11.9083 0.5479 27.9773
SNU-410 CTRP2 4.3334 12.5951 1.2529 22.987
PaTu 8902 CTRP2 4.3889 14.8007 0.2202 26.045
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 -4.3404 0.8923 -4.4005 67.2604
LOX-IMVI CTRP2 -4.9844 -2.1695 -4.9849 73.1038
COLO 792 CTRP2 -4.444 -1.7598 -4.4444 69.678
A2058 CTRP2 -3.7993 -1.2983 -3.7997 65.5012
IGR-37 CTRP2 -3.7774 -1.535 -3.7776 65.3929
Hs 294T CTRP2 -3.746 -1.861 -3.746 65.212
IGR-1 CTRP2 -3.6233 -1.3602 -3.6235 64.37
Hs 940.T CTRP2 -3.4303 0.9435 -3.4642 62.4376
Hs 944.T CTRP2 -3.3886 -0.1712 -3.3932 62.6453
G-361 CTRP2 -3.2088 -1.1332 -3.2089 61.6325
Hs 936.T CTRP2 -2.999 -0.2031 -3.0011 60.178
HT-144 CTRP2 -2.4985 0.721 -2.507 56.8249
SK-MEL-3 CTRP2 -2.4153 1.5655 -2.449 56.1521
K029AX CTRP2 -2.3685 1.0225 -2.3817 55.9497
WM88 CTRP2 -2.3445 1.8787 -2.3928 55.6477
WT2-iPS CTRP2 -2.1667 3.826 -2.423 54.1342
HMCB CTRP2 -2.1593 0.0335 -2.1599 54.649
A101D CTRP2 -2.153 0.4255 -2.1552 54.5962
MeWo CTRP2 -2.1488 0.6857 -2.1533 54.5559
COLO 800 CTRP2 -1.7089 2.501 -1.7747 51.5887
WM266-4 CTRP2 -1.696 1.2306 -1.7039 51.5562
Hs 852.T CTRP2 -1.6416 7.1337 -2.6644 50.8856
SK-MEL-5 CTRP2 -1.5225 1.2183 -1.5282 50.4096
COLO 829 CTRP2 -1.4719 1.7425 -1.4889 50.0735
RVH-421 CTRP2 -1.4592 1.0113 -1.462 49.9901
Mel JuSo CTRP2 -1.4438 1.7792 -1.4615 49.889
IPC-298 CTRP2 -1.344 1.7683 -1.3593 49.2303
SK-MEL-30 CTRP2 -1.2728 1.8424 -1.2889 48.7605
UACC-257 CTRP2 -1.1841 2.6834 -1.2411 48.2085
IGR-39 CTRP2 -1.0485 5.1302 -1.4672 47.6111
WM793 CTRP2 -1.0426 2.2431 -1.0686 47.2519
Hs 688(A).T CTRP2 -1.0018 5.7689 -1.5719 47.4367
Hs 895.T CTRP2 -0.9929 4.5822 -1.2915 47.1925
MDA-MB-435S CTRP2 -0.8388 2.5456 -0.8737 45.9216
WM1799 CTRP2 -0.5439 3.1152 -0.6064 44.0319
CJM [Human melanoma] CTRP2 -0.5328 1.3615 -0.5337 43.8208
A-375 CTRP2 -0.483 1.6513 -0.4853 43.4931
WM983B CTRP2 -0.225 9.3412 -1.9138 44.2799
Hs 839.T CTRP2 -0.2035 3.9553 -0.3381 41.9581
WM115 CTRP2 -0.1889 4.4595 -0.4003 42.0281
SK-MEL-28 CTRP2 0.7872 3.472 0.7545 35.1312
UACC-62 CTRP2 1.0687 3.1294 1.0594 33.1797
SK-MEL-2 CTRP2 1.2759 2.8892 1.2737 31.7756
SK-MEL-24 CTRP2 2.0088 6.5322 1.4979 28.6265
Malme-3M CTRP2 3.38 10.294 1.4313 24.8208
SK-MEL-31 CTRP2 3.4136 9.9247 1.634 24.0312
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 -5.0864 4.0473 -5.6217 66.8106
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-N-DZ CTRP2 -6.5328 -0.9912 -6.567 78.4802
IMR-32 CTRP2 -5.9507 2.9289 -6.3461 70.8126
SK-N-FI CTRP2 -5.4822 -2.7373 -5.4824 76.2956
Kelly CTRP2 -5.0015 -1.9943 -5.0023 73.102
CHP-126 CTRP2 -4.7004 1.6829 -4.8408 68.0448
SK-N-SH CTRP2 -4.5301 -0.016 -4.5539 69.033
SK-N-AS CTRP2 -4.2659 0.1214 -4.2886 67.5572
KP-N-SI9s CTRP2 -3.5832 -0.8663 -3.5842 64.0384
NB1 CTRP2 -3.0301 0.2156 -3.0364 60.301
NH-6 CTRP2 -2.4742 19.6583 -8.7172 52.4033
SK-N-BE(2) CTRP2 -1.2213 9.0894 -2.884 48.9414
CHP-212 CTRP2 -0.9838 4.6661 -1.2981 47.1499
KP-N-YN CTRP2 8.3242 25.6992 -1.9537 23.8603
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-869 CTRP2 -0.7123 5.5134 -1.1914 45.679
SNU-245 CTRP2 0.7678 15.0571 -3.3669 42.327
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TC71 CTRP2 -6.0598 -2.7076 -6.0608 79.2328
A-673 CTRP2 -4.976 -1.276 -4.9808 72.4324
SK-ES-1 CTRP2 -4.3041 -0.3269 -4.316 68.0982
SaOS-2 CTRP2 -4.1009 -0.8574 -4.104 67.2421
SK-N-MC CTRP2 -3.8563 0.2551 -3.8751 65.2353
Hs 888.T CTRP2 -2.6528 7.8785 -4.0045 55.1816
G-292 clone A141B1 CTRP2 -2.3499 4.3125 -2.7084 54.9939
MG-63 CTRP2 -2.0866 3.5852 -2.2989 53.7344
CAL-78 CTRP2 -1.8229 0.177 -1.8232 52.4115
SJSA-1 CTRP2 -1.2248 3.8055 -1.4086 48.5428
HOS CTRP2 -0.6268 2.1329 -0.6392 44.4748
Hs 822.T CTRP2 1.6759 7.918 0.6603 32.3457
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 58 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 CTRP2 -7.5668 -5.982 -7.5668 90.0344
CAL-85-1 CTRP2 -5.3354 -2.1762 -5.3364 75.0795
Hs 578T CTRP2 -4.3072 -2.8357 -4.3072 68.9594
AU565 CTRP2 -4.171 -0.6839 -4.176 67.5699
MDA-MB-468 CTRP2 -3.6054 -0.3093 -3.6102 64.028
MDA-MB-157 CTRP2 -3.4839 2.274 -3.6185 61.9009
CAL-51 CTRP2 -3.2284 2.5267 -3.3761 60.4253
EFM-192A CTRP2 -3.0497 1.0373 -3.0775 60.1744
HCC202 CTRP2 -2.5682 2.5974 -2.6858 56.7768
HCC38 CTRP2 -2.5385 1.4383 -2.5698 56.9439
HCC1428 CTRP2 -1.9482 1.5148 -1.9679 53.1919
BT-549 CTRP2 -1.5949 4.31 -1.8911 50.7907
SK-BR-3 CTRP2 -1.5778 2.1861 -1.6173 50.7607
BT-20 CTRP2 -1.4571 2.428 -1.5072 49.9765
MDA-MB-415 CTRP2 -1.3304 2.5452 -1.3835 49.1562
MDA-MB-453 CTRP2 -1.3076 8.0232 -2.595 49.2776
ZR-75-1 CTRP2 -0.9107 3.6466 -1.0509 46.5294
HCC1500 CTRP2 -0.3646 4.3359 -0.5685 43.1397
MDA-MB-231 CTRP2 0.0589 7.5422 -0.9505 41.9376
HCC1143 CTRP2 0.08 3.5333 0.0108 39.9355
HCC1419 CTRP2 1.1197 7.4666 0.2239 35.4462
ZR-75-30 CTRP2 1.474 9.2679 -0.0837 34.989
T-47D CTRP2 1.5743 9.6724 -0.1457 34.8049
BT-474 CTRP2 1.6893 8.3257 0.5197 32.7027
MDA-MB-361 CTRP2 1.9315 15.5623 -2.4628 52.4285
Hs 578Bst CTRP2 3.5353 14.261 -0.3051 29.5428
BT164 CTRP2 -4.9821 -1.7475 -4.9838 72.8314
BT 145 CTRP2 -4.3954 -1.8352 -4.3957 69.4002
BT 504 CTRP2 -3.9764 1.7032 -4.0814 64.7797
BT 482 CTRP2 -3.9671 0.2868 -3.989 65.8308
BT 112 CTRP2 -3.2932 1.516 -3.3538 61.3587
BT 428 CTRP2 -3.2489 -0.1768 -3.2525 61.7706
BT 231 CTRP2 -2.9499 -0.1106 -2.9523 59.8479
BT 286 CTRP2 -2.7953 2.1007 -2.8781 58.267
BT 422 CTRP2 -2.3719 -0.1119 -2.3725 56.0614
BT 131 CTRP2 -2.3376 2.1953 -2.4073 55.534
BT 179 CTRP2 -2.1663 1.9851 -2.2147 54.5234
BT 416 CTRP2 -2.0569 0.0455 -2.0573 53.9686
BT 159 CTRP2 -1.8225 -0.9127 -1.8225 52.4107
BT 228 CTRP2 -1.7756 2.6371 -1.8558 51.9999
BT 359 CTRP2 -1.6216 3.0331 -1.7322 51.0114
BT 245 CTRP2 -1.3004 2.3257 -1.3385 48.9546
BT147 CTRP2 -1.267 9.3852 -3.0437 49.1623
BT 440 CTRP2 -1.2164 4.8118 -1.5802 48.571
BT 172 CTRP2 -1.1944 6.4438 -1.9681 48.5935
BT 239 CTRP2 -0.9629 9.1181 -2.6175 47.7662
BT 271 CTRP2 -0.8046 3.5103 -0.9212 45.8198
BT 216 CTRP2 -0.3082 7.713 -1.4064 44.0838
BT 328 CTRP2 -0.2247 5.1813 -0.5823 42.5371
BT 224 CTRP2 -0.0103 3.8863 -0.1233 40.6443
BT 139 CTRP2 0.0656 2.6052 0.0525 39.8723
BT 187 CTRP2 0.3659 6.2307 -0.2045 39.3012
BT 330 CTRP2 0.8589 8.0021 -0.2485 37.5179
BT 232 CTRP2 1.0866 11.7779 -1.5578 39.1536
BT 248 CTRP2 1.6675 17.3274 -3.5599 40.0625
BT 444 CTRP2 1.9703 12.1183 -0.8152 35.044
BT 320 CTRP2 6.7277 9.6577 4.7707 4.1701
BT 340 CTRP2 7.4593 21.1011 -0.3397 21.3893
⏷ Show the Full List of 58 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AM-38 CTRP2 -9.5848 -1.4789 -9.6899 85.2924
42-MG-BA CTRP2 -7.1523 1.5436 -7.4247 75.9203
SF539 CTRP2 -5.353 -3.3896 -5.353 75.8277
D283 Med CTRP2 -5.3287 -0.1709 -5.3654 72.8802
GOS-3 CTRP2 -4.1192 17.9493 -9.6072 56.2936
Hs 683 CTRP2 -3.5474 -1.2424 -3.5476 63.8628
DK-MG CTRP2 -3.3081 -1.4534 -3.3081 62.3006
KNS-60 CTRP2 -3.2125 -2.7476 -3.2125 61.6705
M059K CTRP2 -3.1 -1.3916 -3.1 60.9188
KALS-1 CTRP2 -2.8227 0.8742 -2.8399 58.8438
SF268 CTRP2 -2.3468 -0.4326 -2.3469 55.9007
SNB-75 CTRP2 -1.9587 1.5245 -1.9789 53.2591
YKG-1 CTRP2 -1.6696 5.2218 -2.1646 51.1587
TM-31 CTRP2 -1.5531 3.6143 -1.732 50.5668
A-172 CTRP2 -1.5282 11.4609 -4.14 50.2523
CCF-STTG1 CTRP2 -1.4375 2.7592 -1.512 49.8514
YH-13 CTRP2 -1.2012 2.8559 -1.2727 48.3294
U-118MG CTRP2 -1.1758 4.2994 -1.4366 48.2804
SW1088 CTRP2 -0.7975 4.0789 -0.9921 45.8762
GMS-10 CTRP2 -0.6979 3.778 -0.8415 45.1727
U-251MG CTRP2 -0.3941 11.7792 -3.0861 45.8174
8-MG-BA CTRP2 -0.3447 2.6683 -0.3704 42.634
Becker CTRP2 -0.2873 3.3892 -0.3617 42.3709
GaMG CTRP2 0.788 5.4068 0.4686 35.9886
KNS-81 CTRP2 0.9481 6.8617 0.2398 36.0213
T98G CTRP2 0.9669 6.5843 0.3468 35.6711
KNS-42 CTRP2 5.3019 17.4847 -0.3058 25.4448
DBTRG-05MG CTRP2 5.3126 13.2919 1.7941 18.8604
SW1783 CTRP2 6.374 17.3376 0.6701 20.4597
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EN CTRP2 -6.7555 -3.6296 -6.7559 83.4577
JHUEM-1 CTRP2 -6.2463 -4.1361 -6.2464 81.5164
MFE-296 CTRP2 -5.0918 3.6389 -5.5467 67.2769
AN3-CA CTRP2 -4.6455 -1.8214 -4.6462 70.928
ESS-1 CTRP2 -4.2258 -1.9777 -4.2259 68.3559
JHUEM-7 CTRP2 -4.1441 0.0632 -4.1627 66.9502
HEC-151 CTRP2 -3.1393 -1.1609 -3.1394 61.174
MFE-319 CTRP2 -2.26 -0.1777 -2.2603 55.3207
HEC-1-A CTRP2 -2.0865 7.2132 -3.1738 52.9565
JHUEM-3 CTRP2 -0.0088 6.2453 -0.6176 41.6653
HEC-50B CTRP2 1.3956 10.1416 -0.5297 36.258
EFE-184 CTRP2 1.627 6.3023 1.1507 31.0073
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
UO-31 CTRP2 -3.9914 4.2752 -4.4806 62.6193
KMRC-3 CTRP2 -3.2957 -0.3111 -3.2985 62.096
KMRC-1 CTRP2 -2.9483 -1.0302 -2.9484 59.9049
CAL-54 CTRP2 -2.933 1.6108 -2.9862 59.2614
786-O CTRP2 -1.0723 1.3697 -1.0759 47.4184
VMRC-RCZ CTRP2 -0.3961 4.7259 -0.6732 43.4696
KMRC-2 CTRP2 0.2557 5.1984 -0.0637 39.4203
Caki-2 CTRP2 0.5985 6.6989 -0.0897 38.1347
ACHN CTRP2 0.7052 7.1852 -0.1296 37.8212
VMRC-RCW CTRP2 1.014 4.3323 0.9097 33.8533
TUHR10TKB CTRP2 1.0376 4.6902 0.8816 33.8607
RCC10RGB CTRP2 3.5314 11.2888 1.117 25.4608
TUHR14TKB CTRP2 6.3916 19.4508 -0.3717 34.7771
Caki-1 CTRP2 7.0183 18.4295 0.6435 19.3324
⏷ Show the Full List of 14 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1033 CTRP2 -7.3329 5.5418 -8.4205 70.9154
SNU-C1 CTRP2 -4.8481 -0.9157 -4.8562 71.4561
GP2d CTRP2 -4.0591 3.2772 -4.3682 63.7591
SNU-61 CTRP2 -3.8653 2.8193 -4.0909 63.3103
SNU-407 CTRP2 -3.247 0.1494 -3.2546 61.6744
RKO CTRP2 -2.9329 -1.4761 -2.9329 59.8074
SNU-C4 CTRP2 -2.5403 1.1323 -2.5599 57.022
COLO 320 CTRP2 -2.4727 0.902 -2.4847 56.634
T84 CTRP2 -2.38 0.7829 -2.3883 56.054
NCI-H747 CTRP2 -2.2877 1.0512 -2.3003 55.4274
MDST8 CTRP2 -2.1524 0.8469 -2.1591 54.5688
HCT 8 CTRP2 -1.9649 0.7709 -1.9689 53.3425
CW-2 CTRP2 -1.5953 5.3882 -2.1234 50.742
CCK-81 CTRP2 -1.595 2.7679 -1.678 50.8548
CL-11 CTRP2 -1.5481 5.6723 -2.1429 50.4745
LoVo CTRP2 -1.4057 4.1382 -1.6563 49.6694
HCT 15 CTRP2 -1.1528 1.507 -1.1592 47.9575
KM12 CTRP2 -1.0991 3.1639 -1.1944 47.6902
LS123 CTRP2 -1.0615 2.8678 -1.1275 47.4198
SNU-C5 CTRP2 -0.8967 4.9144 -1.2547 46.6608
C2BBe1 CTRP2 -0.816 14.5802 -4.7426 47.8982
COLO201 CTRP2 -0.7386 3.135 -0.8123 45.3276
SW948 CTRP2 -0.6893 3.5074 -0.7986 45.064
NCI-H508 CTRP2 -0.4472 3.4756 -0.5389 43.4573
SW1417 CTRP2 -0.3283 6.6958 -1.0986 43.7932
NCI-H716 CTRP2 -0.2372 4.0126 -0.382 42.1997
COLO 678 CTRP2 0.1713 8.5643 -1.1945 41.8549
LS1034 CTRP2 0.2803 3.9203 0.1812 38.6949
SW1116 CTRP2 0.6244 6.6593 -0.0493 37.9416
SW620 CTRP2 0.9646 7.818 -0.068 36.7216
RCM-1 [Human ESC] CTRP2 1.5757 6.7695 0.9518 31.8049
HT-55 CTRP2 1.5938 6.1529 1.1573 31.0961
HCC-56 CTRP2 1.873 6.3988 1.3905 29.4205
SNU-503 CTRP2 2.4658 29.6355 -8.8518 42.3552
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuH-6 CTRP2 -3.476 1.7273 -3.5595 62.2254
SNU-398 CTRP2 -3.1146 -0.6878 -3.1151 60.9834
JHH-1 CTRP2 -2.3604 0.3369 -2.363 55.965
SNU-886 CTRP2 -2.3567 2.3382 -2.4389 55.614
HLF CTRP2 -2.0572 1.8105 -2.0922 53.862
PLC/PRF/5 CTRP2 -1.3672 3.2935 -1.4923 49.4126
SNU-423 CTRP2 -1.1394 1.7288 -1.15 47.8735
SK-HEP-1 CTRP2 -0.5573 1.8111 -0.562 43.9941
JHH-2 CTRP2 -0.5117 4.0128 -0.6756 44.0103
SNU-475 CTRP2 -0.487 2.4201 -0.5058 43.5615
HuH-1 CTRP2 0.2877 4.2637 0.1433 38.7702
SNU-387 CTRP2 1.037 3.646 1.0025 33.4741
JHH-4 CTRP2 1.2754 5.2493 1.0334 32.5631
JHH-6 CTRP2 1.5425 2.4482 1.5425 29.9925
SNU-761 CTRP2 2.0368 7.2184 1.3021 29.1892
SNU-449 CTRP2 2.4132 4.9612 2.3162 24.521
JHH-5 CTRP2 3.3109 16.6051 -1.6571 33.0868
Hep-G2 CTRP2 3.9445 10.4837 1.9001 21.6899
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 101 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H520 CTRP2 -8.5047 2.0984 -8.9563 77.6827
DV-90 CTRP2 -8.1209 -2.1634 -8.1499 84.5435
NCI-H1341 CTRP2 -6.9889 -4.5263 -6.9889 85.6487
NCI-H522 CTRP2 -6.5779 -3.4199 -6.5783 82.4284
DMS 114 CTRP2 -6.479 -2.5014 -6.4826 80.723
NCI-H810 CTRP2 -6.2069 -3.7027 -6.2069 80.9735
DMS 273 CTRP2 -6.0596 -3.0523 -6.06 79.6097
HCC1438 CTRP2 -5.9584 -3.6848 -5.9585 79.5977
NCI-H510A CTRP2 -5.3412 -0.743 -5.3593 73.6416
NCI-H2081 CTRP2 -5.0374 0.8115 -5.119 70.4512
NCI-H1703 CTRP2 -4.9894 -2.5286 -4.9895 73.298
NCI-H23 CTRP2 -4.8767 -0.9658 -4.8844 71.6476
COLO 668 CTRP2 -4.7188 0.9372 -4.7962 68.9528
NCI-H2029 CTRP2 -4.5535 1.3319 -4.654 67.7999
NCI-H1694 CTRP2 -4.4409 -1.2524 -4.443 69.4429
LCLC-97TM1 CTRP2 -4.3715 -1.2533 -4.3734 69.0344
COR-L51 CTRP2 -4.3471 -1.7329 -4.3475 69.0691
NCI-H1105 CTRP2 -4.2213 -1.6455 -4.2217 68.2576
LK2 CTRP2 -4.2134 0.0891 -4.2341 67.304
NCI-H841 CTRP2 -4.0259 -1.6112 -4.0261 67.009
SK-MES-1 CTRP2 -3.9211 0.019 -3.9349 65.7413
VMRC-LCD CTRP2 -3.7819 2.6803 -3.9831 63.0426
NCI-H2110 CTRP2 -3.763 -1.3185 -3.7634 65.2708
NCI-H2171 CTRP2 -3.7117 1.9131 -3.8226 63.3093
COR-L279 CTRP2 -3.5471 1.9143 -3.6498 62.4724
NCI-H1944 CTRP2 -3.476 1.9775 -3.5809 62.0613
Sq-1 CTRP2 -3.3987 -0.4594 -3.401 62.7813
NCI-H1623 CTRP2 -3.3855 0.3173 -3.398 62.4629
NCI-H524 CTRP2 -3.3616 -0.5347 -3.3633 62.5603
NCI-H2087 CTRP2 -3.3179 0.4849 -3.3333 61.9913
NCI-H1568 CTRP2 -3.2514 -0.1523 -3.2553 61.7807
NCI-H2196 CTRP2 -3.21 0.6825 -3.229 61.2681
ChaGo-K-1 CTRP2 -3.1814 0.5246 -3.1955 61.1522
Calu-6 CTRP2 -3.0664 -1.2521 -3.0664 60.6931
NCI-H661 CTRP2 -3.024 -1.8102 -3.024 60.4146
EPLC-272H CTRP2 -2.6954 2.2286 -2.7844 57.6421
NCI-H889 CTRP2 -2.6597 0.6127 -2.6683 57.874
NCI-H1651 CTRP2 -2.6525 0.176 -2.6555 57.8865
NCI-H1184 CTRP2 -2.6391 1.0294 -2.6574 57.6631
DMS 53 CTRP2 -2.5891 1.8629 -2.6454 57.1384
RERF-LC-MS CTRP2 -2.5842 0.4343 -2.5893 57.4146
NCI-H446 CTRP2 -2.5176 0.9617 -2.5317 56.9101
NCI-H1693 CTRP2 -2.3054 4.2148 -2.6416 54.7878
LUDLU-1 CTRP2 -2.2955 1.418 -2.3197 55.4271
NCI-H1339 CTRP2 -2.2863 0.4608 -2.2895 55.471
NCI-H1869 CTRP2 -2.2191 1.8365 -2.2606 54.8774
NCI-H838 CTRP2 -2.1746 0.4344 -2.177 54.7381
NCI-H2286 CTRP2 -2.081 2.3216 -2.1492 53.9388
LC-1/sq-SF CTRP2 -1.9617 2.3304 -2.0255 53.196
NCI-H2170 CTRP2 -1.8546 2.6068 -1.936 52.4965
NCI-H1666 CTRP2 -1.7922 2.0246 -1.8299 52.15
NCI-H1792 CTRP2 -1.7681 2.4753 -1.8346 51.9653
NCI-H647 CTRP2 -1.7081 5.304 -2.2261 51.3616
Lu-65 CTRP2 -1.6408 6.0651 -2.3484 50.9474
NCI-H1915 CTRP2 -1.6359 3.0204 -1.746 51.1016
NCI-H1435 CTRP2 -1.5903 3.2394 -1.7226 50.8085
LXF 289 CTRP2 -1.4635 1.4926 -1.4736 50.0186
HOP-62 CTRP2 -1.4462 3.5447 -1.6082 49.91
NCI-H1373 CTRP2 -1.3975 5.534 -1.9437 49.6506
NCI-H1650 CTRP2 -1.3366 3.1943 -1.4486 49.2158
COR-L95 CTRP2 -1.3171 7.5176 -2.4351 49.2998
NCI-H2342 CTRP2 -1.272 4.3844 -1.556 48.8724
NCI-H322 CTRP2 -1.2678 2.4244 -1.3105 48.7441
HOP-92 CTRP2 -1.098 4.9673 -1.4848 76.5735
NCI-H2023 CTRP2 -1.0769 5.722 -1.6416 47.8592
COR-L105 CTRP2 -1.0752 5.0763 -1.4841 47.7621
COR-L47 CTRP2 -0.9385 69.3621 -31.6068 49.5939
NCI-H1092 CTRP2 -0.8825 8.1935 -2.1946 47.2271
HCC4006 CTRP2 -0.8026 2.3928 -0.8286 45.6676
RERF-LC-Ad2 CTRP2 -0.7942 8.8034 -2.3195 46.9136
NCI-H1563 CTRP2 -0.7869 4.5825 -1.0686 45.9132
NCI-H1355 CTRP2 -0.7174 5.6737 -1.2371 45.7515
T3M-10 CTRP2 -0.6668 2.7993 -0.7109 44.8045
NCI-H2444 CTRP2 -0.6586 1.3429 -0.6597 44.6594
KNS-62 CTRP2 -0.6464 2.116 -0.6586 44.6047
NCI-H1395 CTRP2 -0.6317 3.4221 -0.7281 44.6687
NCI-H460 CTRP2 -0.6135 4.003 -0.7831 44.6719
NCI-H226 CTRP2 -0.5612 3.2187 -0.6337 44.1653
EBC-1 CTRP2 -0.4165 5.6362 -0.8994 43.9165
NCI-H2122 CTRP2 -0.3196 4.1172 -0.4854 42.7768
A-549 CTRP2 -0.2897 6.8307 -1.0979 43.6229
NCI-H2126 CTRP2 -0.284 1.7956 -0.2864 42.168
SK-LU-1 CTRP2 -0.2257 5.9046 -0.7607 42.8463
NCI-H2228 CTRP2 -0.2004 8.1573 -1.4456 43.6784
HCC2935 CTRP2 -0.1762 5.9451 -0.7175 42.5581
PC-14 CTRP2 -0.0447 1.622 -0.0452 40.5681
NCI-H1793 CTRP2 0.1039 5.5538 -0.3115 40.5968
NCI-H441 CTRP2 0.1058 9.0275 -1.4399 42.4478
NCI-H2085 CTRP2 0.2876 4.6066 0.0879 38.9168
EKVX CTRP2 0.3116 4.5833 0.1178 38.7451
SW1573 CTRP2 0.3621 7.1346 -0.4854 39.9005
Calu-1 CTRP2 0.5695 5.703 0.1591 37.641
DMS 454 CTRP2 0.6991 9.836 -1.1316 39.7885
NCI-H209 CTRP2 0.7312 16.8136 -4.2233 43.1469
HCC1195 CTRP2 0.8353 6.4316 0.2493 36.4096
NCI-H2172 CTRP2 0.8442 3.3153 0.8223 34.7166
LOU-NH91 CTRP2 1.1202 3.728 1.0833 32.928
SW1271 CTRP2 2.0658 8.963 0.6636 31.0807
NCI-H1755 CTRP2 2.2695 4.9073 2.1703 25.4856
IA-LM CTRP2 2.3332 7.7408 1.4311 27.8376
Hs 888.Lu CTRP2 -3.6064 5.5119 -4.3473 60.159
⏷ Show the Full List of 101 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 -7.4453 3.5876 -8.0866 73.5701
H-STS CTRP2 -3.7547 -3.112 -3.7547 65.2833
P-STS CTRP2 -2.2355 2.0802 -2.2927 54.9352
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 -5.9999 -1.8046 -6.0068 77.8229
COV434 CTRP2 -7.3679 -3.8688 -7.3686 86.0431
A2780 CTRP2 -5.6461 -2.8985 -5.6463 77.3183
COV362 CTRP2 -4.8527 6.429 -5.9551 63.7841
OVK18 CTRP2 -4.7263 -2.1697 -4.7265 71.5562
COV644 CTRP2 -4.327 -0.8145 -4.3319 68.5426
TOV-112D CTRP2 -4.1799 0.8096 -4.2297 66.5472
OVCAR-4 CTRP2 -2.9259 0.1555 -2.9306 59.6518
OC 314 CTRP2 -2.5905 -1.4682 -2.5905 57.5266
TYK-nu CTRP2 -2.4349 10.7439 -4.8126 53.597
OAW28 CTRP2 -2.3015 1.7849 -2.3429 55.4009
OV7 CTRP2 -2.294 2.9405 -2.4337 55.0875
Caov-3 CTRP2 -2.1137 3.693 -2.3445 53.8659
TOV-21G CTRP2 -1.9726 1.3307 -1.987 53.3634
OV56 CTRP2 -1.966 4.8081 -2.3937 52.8221
JHOS-2 CTRP2 -1.6238 6.3144 -2.3994 50.8448
JHOM-1 CTRP2 -1.5679 1.9397 -1.5948 50.7013
MCAS CTRP2 -1.5106 1.6299 -1.525 50.3287
IGROV-1 CTRP2 -1.483 3.3283 -1.6194 50.1393
EFO-21 CTRP2 -1.4477 4.4264 -1.7539 49.9235
OAW42 CTRP2 -1.3773 1.6628 -1.3902 49.4492
EFO-27 CTRP2 -0.764 4.134 -0.9649 45.6726
OVCAR-5 CTRP2 -0.2256 4.0822 -0.3796 42.1443
SNU-840 CTRP2 -0.035 4.6528 -0.2686 41.0867
SK-OV-3 CTRP2 0.0412 6.7331 -0.7074 41.6128
HEY A8 CTRP2 0.5127 10.3388 -1.5345 41.0671
FU-OV-1 CTRP2 0.9953 8.6633 -0.3508 37.2493
OV-90 CTRP2 1.2145 8.6516 -0.1127 35.9417
OVCAR-8 CTRP2 1.2506 6.7278 0.6114 33.9291
RMG-I CTRP2 4.4315 13.935 0.6857 24.5711
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 -3.0055 7.2555 -4.1875 56.8197
Yamato-SS CTRP2 -2.9191 -0.0371 -2.9219 59.6387
G-402 CTRP2 -8.2013 -4.9847 -8.2014 90.365
TE 617.T CTRP2 -7.4714 -3.7329 -7.4726 86.1095
TTC-709 CTRP2 -6.986 -3.4012 -6.9871 83.986
Tm87-16 CTRP2 -6.7017 -4.3589 -6.7017 84.1135
BT-16 CTRP2 -6.6439 -4.6445 -6.6439 84.0762
G-401 CTRP2 -6.5911 -2.626 -6.5944 81.3336
TE 441.T CTRP2 -6.159 -0.9474 -6.1865 77.1708
BT-12 CTRP2 -5.9408 -4.3631 -5.9408 79.7765
A-204 CTRP2 -5.5072 6.065 -6.5679 66.0105
KYM-1 CTRP2 -4.9161 33.0243 -17.3966 54.9099
RD CTRP2 -4.5814 -0.0191 -4.6061 69.2926
MES-SA CTRP2 -4.0398 -1.1016 -4.0412 66.9657
SK-UT-1 CTRP2 -2.6899 2.3159 -2.7864 57.5777
GCT CTRP2 -2.605 0.8534 -2.6179 57.4841
Hs 729.T CTRP2 -2.3861 0.7483 -2.3939 56.0973
SW982 CTRP2 -1.824 1.9531 -1.859 52.3589
HT-1080 CTRP2 -1.6008 2.9137 -1.698 50.8864
Rh18 CTRP2 -0.4629 2.1173 -0.4721 43.3776
SK-LMS-1 CTRP2 0.2441 5.9312 -0.2551 39.9009
RKN CTRP2 0.4183 4.6399 0.223 38.0527
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 1.1647 8.7111 -0.1888 36.2915
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP2 -4.3459 -0.9462 -4.3496 68.7262
MPP 89 CTRP2 -3.8357 -0.991 -3.8369 65.6642
IST-Mes1 CTRP2 -2.3151 0.9191 -2.3252 55.6194
JL-1 CTRP2 -1.3242 0.5696 -1.3246 49.0912
NCI-H2452 CTRP2 -0.65 4.7041 -0.944 45.0815
NCI-H2052 CTRP2 0 9.3931 -1.6944 43.17
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC CTRP2 -5.889 -1.0714 -5.9079 76.3548
VCaP CTRP2 -5.7798 -3.203 -5.7798 78.2745
DU145 CTRP2 -0.8103 5.2838 -1.2432 46.2136
NCI-H660 CTRP2 0.4352 9.1829 -1.1493 40.7791
PaCa-3 CTRP2 0.5451 13.5172 -2.8855 42.5405
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 CTRP2 -2.3922 3.1102 -2.559 55.6039
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HGC-27 CTRP2 -6.5423 -4.2429 -6.5423 83.1982
SNU-1 CTRP2 -5.9719 0.5553 -6.0742 74.2398
SNU-16 CTRP2 -5.8755 -5.1009 -5.8755 79.4115
IM95 CTRP2 -4.65 -1.6402 -4.6511 70.8684
NCC-StC-K140 CTRP2 -3.5086 2.1347 -3.6303 62.1227
SNU-601 CTRP2 -3.0801 1.5096 -3.1324 60.1566
Hs 746.T CTRP2 -2.4793 2.9898 -2.6364 56.1366
NUGC-3 CTRP2 -2.1209 0.0452 -2.1214 54.3937
SNU-216 CTRP2 -1.9784 2.2835 -2.0394 53.3062
SH-10-TC CTRP2 -1.7356 0.6574 -1.7374 51.828
HuG1-N CTRP2 -1.5623 3.3711 -1.7091 50.6307
ECC10 CTRP2 -0.8292 5.4185 -1.2957 46.3572
OCUM-1 CTRP2 0.0183 9.7954 -1.834 43.2582
MKN74 CTRP2 0.1441 6.4747 -0.5173 40.8419
MKN7 CTRP2 0.4798 4.6587 0.286 37.646
LMSU CTRP2 0.8195 5.3405 0.5179 35.7331
KE-39 CTRP2 2.3123 11.6426 -0.2549 32.7685
KATO III CTRP2 3.7272 11.2571 1.3225 24.2694
SNG-M CTRP2 -1.8514 1.223 -1.8612 52.5781
SNU-685 CTRP2 -0.7606 2.433 -0.7872 45.3907
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CTRP2 -3.4207 -1.5751 -3.4207 63.0504
FTC-238 CTRP2 -3.0996 -1.6072 -3.0996 60.9178
FTC-133 CTRP2 -1.7477 0.6761 -1.7496 51.908
ML-1 [Human leukemia] CTRP2 -1.52 7.0619 -2.5095 50.294
TT2609-C02 CTRP2 0.4374 9.6127 -1.3173 41.0265
Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BICR 22 CTRP2 -5.7382 -2.9658 -5.7384 77.8709
CAL-33 CTRP2 -3.5531 -1.759 -3.5531 63.9329
SCC-25 CTRP2 -3.3694 -1.5811 -3.3695 62.7108
BICR 18 CTRP2 -3.237 0.0236 -3.2427 61.6469
PE/CA-PJ15 CTRP2 -3.2193 0.4153 -3.2315 61.4205
HSC-2 CTRP2 -3.1484 -1.6989 -3.1484 61.2432
PE/CA-PJ34 (clone C12) CTRP2 -3.051 -0.3753 -3.0524 60.5369
SCC-4 CTRP2 -2.9177 -1.4066 -2.9177 59.7061
PE/CA-PJ41 (clone D2) CTRP2 -2.6355 3.0582 -2.8113 56.9837
BICR 6 CTRP2 -2.6053 -0.3956 -2.6057 57.6147
YD-8 CTRP2 -2.5451 0.7369 -2.5546 57.1221
PE/CA-PJ49 CTRP2 -2.5147 -0.3335 -2.5151 57.0131
BICR 31 CTRP2 -2.2419 2.3567 -2.3202 54.9177
BICR 56 CTRP2 -2.0215 -0.8863 -2.0215 53.7365
SCC-9 CTRP2 -1.1536 0.8059 -1.1542 47.955
FaDu CTRP2 -1.1178 2.0457 -1.1376 47.7408
HSC-4 CTRP2 -0.9141 2.5274 -0.9505 46.4195
⏷ Show the Full List of 17 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BC-3C CTRP2 -4.8454 -0.5177 -4.861 71.0741
647V CTRP2 -3.4607 -2.0783 -3.4607 63.324
RT-112 CTRP2 -2.7746 2.7146 -2.9169 57.8932
RT-4 CTRP2 -2.6653 -0.0162 -2.667 57.9879
HT-1197 CTRP2 -2.1193 1.7228 -2.1518 54.2667
SCaBER CTRP2 -2.0918 0.916 -2.099 54.1687
U-BLC1 CTRP2 -1.6449 2.2391 -1.6899 51.1924
UM-UC-1 CTRP2 -1.4947 2.4654 -1.5489 50.2197
J82 CTRP2 -0.8867 2.4416 -0.9176 46.2308
UM-UC-3 CTRP2 -0.7694 6.1337 -1.4163 46.1733
T24 CTRP2 -0.1064 4.7008 -0.3548 41.5764
KMBC-2 CTRP2 0.4324 5.3631 0.0915 38.3413
HT-1376 CTRP2 2.1988 10.1985 0.2765 31.7546
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 -3.1233 -1.1229 -3.1233 61.0667

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Omacetaxine mepesuccinate
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Fedratinib. Myeloproliferative neoplasm [2A20] [8]
Nilotinib DM7HXWT Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Nilotinib. Myeloproliferative neoplasm [2A20] [9]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Ruxolitinib. Myeloproliferative neoplasm [2A20] [8]
Coadministration of a Drug Treating the Disease Different from Omacetaxine mepesuccinate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Midostaurin. Acute myeloid leukaemia [2A60] [9]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Inotersen. Amyloidosis [5D00] [8]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Siltuximab. Anemia [3A00-3A9Z] [9]
Dupilumab DMOAD2Y Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Dupilumab. Atopic eczema [EA80] [9]
Eribulin DM1DX4Q Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Eribulin. Breast cancer [2C60-2C6Y] [9]
Talazoparib DM1KS78 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Talazoparib. Breast cancer [2C60-2C6Y] [9]
LY2835219 DM93VBZ Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and LY2835219. Breast cancer [2C60-2C6Y] [9]
Pralatrexate DMAO80I Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Pralatrexate. Breast cancer [2C60-2C6Y] [9]
Palbociclib DMD7L94 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Palbociclib. Breast cancer [2C60-2C6Y] [9]
Cabazitaxel DMPAZHC Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Cabazitaxel. Breast cancer [2C60-2C6Y] [9]
Bosutinib DMTI8YE Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Bosutinib. Breast cancer [2C60-2C6Y] [9]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Regorafenib. Colorectal cancer [2B91] [8]
Aflibercept DMT3D5I Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Aflibercept. Colorectal cancer [2B91] [9]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Ardeparin. Coronary thrombosis [BA43] [8]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Danaparoid. Deep vein thrombosis [BD71] [8]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Rivaroxaban. Deep vein thrombosis [BD71] [8]
Polatuzumab vedotin DMF6Y0L Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [9]
Lisocabtagene maraleucel DMP45ME Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Lisocabtagene maraleucel. Diffuse large B-cell lymphoma [2A81] [9]
Axicabtagene ciloleucel DMYHN59 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [9]
Bay 80-6946 DMLOS5R Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Bay 80-6946. Follicular lymphoma [2A80] [9]
Tazemetostat DMWP1BH Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Tazemetostat. Follicular lymphoma [2A80] [8]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Avapritinib. Gastrointestinal stromal tumour [2B5B] [8]
177Lu-DOTATATE DMT8GVU Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [9]
Brentuximab vedotin DMWLC57 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Brentuximab vedotin. Hodgkin lymphoma [2B30] [9]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Teriflunomide. Hyper-lipoproteinaemia [5C80] [10]
Olaratumab DMNYOIX Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Olaratumab. Kaposi sarcoma [2B57] [9]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Denosumab. Low bone mass disorder [FB83] [11]
Brigatinib DM7W94S Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Brigatinib. Lung cancer [2C25] [9]
Lurbinectedin DMEFRTZ Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Lurbinectedin. Lung cancer [2C25] [9]
Osimertinib DMRJLAT Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Osimertinib. Lung cancer [2C25] [9]
Belimumab DM3OBQF Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Belimumab. Lupus erythematosus [4A40] [9]
Inotuzumab ozogamicin DMAC130 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [9]
Ofatumumab DM295PR Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ofatumumab. Mature B-cell leukaemia [2A82] [9]
Obinutuzumab DM3BVAE Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Obinutuzumab. Mature B-cell leukaemia [2A82] [9]
GDC-0199 DMH0QKA Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and GDC-0199. Mature B-cell leukaemia [2A82] [9]
IPI-145 DMWA24P Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and IPI-145. Mature B-cell leukaemia [2A82] [9]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Acalabrutinib. Mature B-cell lymphoma [2A85] [8]
Blinatumomab DMGECIJ Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Blinatumomab. Mature B-cell lymphoma [2A85] [9]
Ibrutinib DMHZCPO Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ibrutinib. Mature B-cell lymphoma [2A85] [9]
Ponatinib DMYGJQO Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ponatinib. Mature B-cell lymphoma [2A85] [9]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Arry-162. Melanoma [2C30] [8]
Ipilimumab DMJTIYK Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ipilimumab. Melanoma [2C30] [9]
LGX818 DMNQXV8 Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and LGX818. Melanoma [2C30] [8]
Carfilzomib DM48K0X Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Carfilzomib. Multiple myeloma [2A83] [9]
Selinexor DMBD4K3 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Selinexor. Multiple myeloma [2A83] [9]
Belantamab mafodotin DMBT3AI Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Belantamab mafodotin. Multiple myeloma [2A83] [9]
Elotuzumab DMEYHG9 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Elotuzumab. Multiple myeloma [2A83] [9]
Daratumumab DMKCIUZ Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Daratumumab. Multiple myeloma [2A83] [9]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Tecfidera. Multiple sclerosis [8A40] [9]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Siponimod. Multiple sclerosis [8A40] [12]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Fingolimod. Multiple sclerosis [8A40] [13]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ocrelizumab. Multiple sclerosis [8A40] [9]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ozanimod. Multiple sclerosis [8A40] [14]
Deflazacort DMV0RNS Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Deflazacort. Muscular dystrophy [8C70] [9]
Romidepsin DMT5GNL Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Romidepsin. Mycosis fungoides [2B01] [9]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Prasugrel. Myocardial infarction [BA41-BA43] [8]
Inebilizumab DMI0RHA Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Inebilizumab. Nervous system paraneoplastic/autoimmune disorder [8E4A] [9]
Atezolizumab DMMF8U0 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Atezolizumab. Non-small cell lung cancer [2C25] [9]
Olaparib DM8QB1D Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Olaparib. Ovarian cancer [2C73] [9]
Rucaparib DM9PVX8 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Rucaparib. Ovarian cancer [2C73] [9]
MK-4827 DMLYGH4 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and MK-4827. Ovarian cancer [2C73] [9]
Brodalumab DMASDQ6 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Brodalumab. Psoriasis [EA90] [9]
Ustekinumab DMHTYK3 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ustekinumab. Psoriasis [EA90] [9]
Tildrakizumab DMLW9HG Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Tildrakizumab. Psoriasis [EA90] [9]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Risankizumab. Psoriasis [EA90] [9]
Ixekizumab DMXW92T Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Ixekizumab. Psoriasis [EA90] [9]
Temsirolimus DMS104F Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Temsirolimus. Renal cell carcinoma [2C90] [9]
Tocilizumab DM7J6OR Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Tocilizumab. Rheumatoid arthritis [FA20] [9]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Canakinumab. Rheumatoid arthritis [FA20] [15]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Rilonacept. Rheumatoid arthritis [FA20] [15]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Golimumab. Rheumatoid arthritis [FA20] [16]
Sarilumab DMOGNXY Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Sarilumab. Rheumatoid arthritis [FA20] [9]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Omacetaxine mepesuccinate when combined with Anthrax vaccine. Sepsis [1G40-1G41] [17]
Mogamulizumab DMISH0Z Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Mogamulizumab. Sezary syndrome [2B02] [9]
PDX-101 DM6OC53 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and PDX-101. Solid tumour/cancer [2A00-2F9Z] [9]
Trabectedin DMG3Y89 Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [9]
LEE011 DMMX75K Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and LEE011. Solid tumour/cancer [2A00-2F9Z] [9]
Triptorelin DMTK4LS Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [9]
Pomalidomide DMTGBAX Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Pomalidomide. Systemic sclerosis [4A42] [9]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Plicamycin. Testicular cancer [2C80] [8]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Caplacizumab. Thrombocytopenia [3B64] [8]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Apixaban. Thrombosis [DB61-GB90] [8]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Cangrelor. Thrombosis [DB61-GB90] [8]
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Brilinta. Thrombosis [DB61-GB90] [8]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Cabozantinib. Thyroid cancer [2D10] [18]
Belatacept DMXLYQF Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Belatacept. Transplant rejection [NE84] [9]
Durvalumab DM4PVDY Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Durvalumab. Ureteral cancer [2C92] [9]
Fluticasone DMGCSVF Moderate Additive immunosuppressive effects by the combination of Omacetaxine mepesuccinate and Fluticasone. Vasomotor/allergic rhinitis [CA08] [9]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Omacetaxine mepesuccinate and Betrixaban. Venous thromboembolism [BD72] [8]
⏷ Show the Full List of 89 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Omacetaxine Mepesuccinate 3.5mg/vial powder 3.5mg/vial Powder Subcutaneous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Omacetaxine mepesuccinate FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7454).
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms. J Exp Clin Cancer Res. 2019 Jul 15;38(1):308. doi: 10.1186/s13046-019-1295-8.
6 Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways. Food Chem Toxicol. 2020 Feb;136:110960. doi: 10.1016/j.fct.2019.110960. Epub 2019 Nov 11.
7 [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Jun;33(6):834-9.
8 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
9 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
10 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
11 Product Information. Lonsurf (tipiracil-trifluridine). Taiho Oncology, Inc., Princeton, NJ.
12 Cerner Multum, Inc. "Australian Product Information.".
13 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
16 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
17 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
18 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]